|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
6
|
Resverlogix Corp.
|
Apr 18, 2019 08:33AM
|
|
Re: Been wondering
|
6
|
Resverlogix Corp.
|
Aug 19, 2019 07:33PM
|
|
Re: Resverlogix Announces Presentations
|
6
|
Resverlogix Corp.
|
Oct 15, 2020 08:48AM
|
|
Re: Did someone already post this?
|
6
|
Resverlogix Corp.
|
Aug 17, 2017 04:23PM
|
|
Re: Third Eye, AHA, US Listing
|
6
|
Resverlogix Corp.
|
Sep 19, 2019 10:08AM
|
|
Re: Lilly to Discontinue Development of Evacetrapib
|
6
|
Resverlogix Corp.
|
Nov 17, 2015 03:08PM
|
|
11 months into BETonMACE
|
6
|
Resverlogix Corp.
|
Oct 10, 2016 12:00PM
|
|
Will Phase 2a Renal trial start tomorrow?
|
6
|
Resverlogix Corp.
|
Jun 14, 2017 10:43PM
|
|
Re: Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
|
6
|
Resverlogix Corp.
|
Jun 14, 2018 03:36PM
|
|
Re: Biogen vs. Resverlogix, CTAD December 5
|
6
|
Resverlogix Corp.
|
Nov 24, 2019 06:34AM
|
|
Re: Biogen CTAD webcast starting now
|
6
|
Resverlogix Corp.
|
Dec 05, 2019 12:03PM
|
|
Re: A little surprised there was no PR about the article.....
|
6
|
Resverlogix Corp.
|
Jan 25, 2016 11:58AM
|
|
Re: Clinical trials query results
|
6
|
Zenith Epigenetics
|
Apr 08, 2021 01:03PM
|
|
Re: New Alkaline Phosphate publication from Dr. Kalantar-Zadeh
|
6
|
Resverlogix Corp.
|
Nov 17, 2019 01:13PM
|
|
Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)
|
6
|
Zenith Epigenetics
|
May 06, 2019 03:19PM
|
|
Re: p-values : are correct
|
6
|
Resverlogix Corp.
|
Feb 24, 2017 09:33AM
|
|
Re: Statistical Considerations
|
6
|
Resverlogix Corp.
|
Mar 06, 2018 03:06PM
|
|
Re: Reports of exempt distribution on SEDAR
|
6
|
Resverlogix Corp.
|
Mar 29, 2018 10:29AM
|
|
Everyone just take a deep breath
|
6
|
Resverlogix Corp.
|
Apr 20, 2017 10:15AM
|
|
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
|
6
|
Resverlogix Corp.
|
Jul 15, 2019 09:19AM
|
